BlossomHill Therapeutics, Inc. (BLSM)
NASDAQ: BLSM · Real-Time Price · USD
13.94
-1.04 (-6.94%)
Oct 16, 2026, 4:00 PM EDT - Market closed
Company Description
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment.
Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
BlossomHill Therapeutics, Inc.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 7, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 69 |
| CEO | Jingrong Jean Cui |
Contact Details
Address: 10255 Science Center Drive, Suite 200 San Diego, California 92121 United States | |
| Phone | (858) 732-3880 |
| Website | bhtherapeutics.com |
Stock Details
| Ticker Symbol | BLSM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 1839970 |
| CUSIP Number | 095130100 |
| ISIN Number | US0951301003 |
| Employer ID | 85-1578711 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jingrong Jean Cui Ph.D. | Scientific Founder, President, Chief Executive Officer and Director |
| Dr. Yishan Li M.B.A., Ph.D. | Co-Founder and Executive Chairman |
| Jason A. Keyes M.B.A. | Chief Financial Officer and Executive Vice President |
| Dr. Geoff Oxnard M.D. | Chief Medical Officer and Executive Vice President |
| Dr. Vincent Liptak J.D., M.B.A., Ph.D. | General Counsel and Executive Vice President |
| Dr. Zachary F. Zimmerman M.D., Ph.D. | Senior Vice President of Clinical Development |
| Dr. Eugene Y. Rui Ph.D. | Senior Vice President of Chemistry |
| Dr. Z. Jesse Shao Ph.D., R.Ph. | Senior Vice President of CMC |
| Dr. Ashley Preston Ph.D. | Senior Vice President and Head of Regulatory Affairs and Quality Assurance |
| Dr. Antonio Garrido-Montalban Ph.D. | Senior Vice President of Drug Substance |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | 10-Q | Quarterly Report |
| Sep 18, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 8-K | Current Report |
| Aug 18, 2026 | SCHEDULE 13D | Filing |
| Aug 17, 2026 | SCHEDULE 13G | Filing |
| Aug 14, 2026 | SCHEDULE 13G | Filing |
| Aug 13, 2026 | SCHEDULE 13D | Filing |
| Aug 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 7, 2026 | 424B4 | Prospectus |